We all know about the condition of heart failure. We just haven’t been able to treat it the right way—until now.

We’ve had to watch the devastating symptoms of heart failure as the disease progresses and the damage becomes irreversible.

It’s time to reshape the treatment course for patients.

Cardiac Dimensions is on a mission to bring more success to the treatment of heart failure patients.

Featured in
MedTech
Strategist

Introducing the Carillon Mitral Contour System®

A completely different and much earlier approach to treating functional mitral regurgitation (FMR) than any other device therapy currently available to patients.

The goal: Treat the condition—not just the symptoms.

The Carillon system is designed to work with the natural structure and function of the heart to help treat the condition of FMR as well as the related symptoms.

We believe the Carillon therapy is a smarter solution to help patients feel better and live longer lives.

Discover the Carillon system

U.S. EMPOWER Clinical Trial

NOW ENROLLING

For heart failure patients with large ventricles + functional mitral regurgitation

LEARN MORE

Our goal is to bring a better treatment option to the millions of people who suffer from heart failure with FMR.

Minimally invasive percutaneous procedure.

Short implant procedure. Usually about an hour.

Doesn’t prevent other treatments if needed.

European studies demonstrate improvement in patient clinical and mechanistic outcomes.

The Carillon therapy is a short and minimally invasive procedure. In several published European studies, the majority of patients experienced an improvement in quality of life, mitral regurgitation, and LV volume.^6,16,17,19

LEARN MORE

>> Show footnotes
Dennis Rottländer, MD; Miriel Gödde, MD; Hubertus Degen, MD; Alev Ögütcü, MD; Michael Haude, MD, PhD. Percutaneous Coronary Sinus-Based Mitral Valve Annuloplasty in Atrial Functional Mitral Regurgitation. JACC: Cardiovascular Interventions. December 28, 2020

Lipiecki, J, Fahrat, H, Séverine, M, et al. Long-term prognosis of patients treated by coronary sinus-based annuloplasty: single centre experience. ESC Heart Failure. October, 2020.

Stephan Heyl, Aria Nikkhoo, Markus Wieszner, Stephan Fichtlscherer, Florian Seeger, Birgit Assmus, Brigitte Luu, Katrin Hemmann, Claudia Walther, Joerg Honold. Comparison of effectiveness and survival after the MitraClip or Carillon procedure for severe functional mitral regurgitation: a single-center retrospective analysis. Arch Med Sci Atheroscler Dis. June, 2020.

Stephan Stöbe, Kristin Kreyer, Daniel Jurisch, Dietrich Pfeiffer, Daniel Lavall, Gerardo Farese, Ulrich Laufs, Andreas Hagendorff. Echocardiographic analysis of acute effects of percutaneous mitral annuloplasty on severity of secondary mitral regurgitation. ESC Heart Failure. May, 2020.

Tobias Friedrich Ruf, Felix Kreidel, Alexander Robert Tamm, Martin Geyer, Omar Hahad, Julia Claudia Zirbs, Ben Luca Schwidtal, Andres Beiras-Fernandez, Klaus K. Witte, Thomas Münzel, Ralph Stephan von Bardeleben. Transcatheter indirect mitral annuloplasty induces annular and left atrial remodelling in secondary mitral regurgitation. ESC Heart Failure. April, 2020.

Lipiecki, J, Kaye DM, Witte KK, et al. Long-Term Survival Following Transcatheter Mitral Valve Repair: Pooled Analysis of Prospective Trials with the Carillon Device. Cardiovascular Revascularization Medicine. February, 2020.

Kałmucki P., Jerzykowska O., Dankowski R., Baszko A., Kramer L., Szyszka A., Siminiak T. Percutaneous Trans-Coronary Venous Mitral Annuloplasty in Patients With Functional Mitral Regurgitation: Analysis of Poznan Carillon Registry Data. J Interv Cardiol. 2016.

Klein, N. et al. Mitral Annuloplasty Device Implantation for Non-Surgical Treatment of Mitral Regurgitation: Clinical Experience after the Approval Studies. Journal of Invasive Cardiology. February, 2016.

Borisenko, O., Haude, M., Hoppe, UC., Siminiak, T., Lipiecki, J., Goldberg, S., Mehta, N., Bouknight, O., Bjessmo S., Reuter DG. Cost-utility analysis of percutaneous mitral valve repair in inoperable patients with functional mitral regurgitation in German settings. BMC Cardiovascular Disorders. 2015;15:43.

Soofi, M.A., Alsamadi F. Restoration of Normal Left Ventricular Geometry after Percutaneous Mitral Annuloplasty: Case Report and Review of Literature. Catheterization and Cardiovascular Interventions. 2014.

Siminiak T, Jerzykowska O, Kałmucki P, Link R, Baszko A. Cardiac resynchronization therapy after percutaneous trans-coronary-venous mitral annuloplasty. Kardiol Pol. 2013;71(12):1293-4.

Woloszyn M, Jerzykowska O, Kałmucki P, Lunk R, Firek L, Kuzemczak M, Siminiak T. Functional assessment of patients after percutaneous mitral valvuloplasty with Carillon device: a preliminary report. Kardiol Pol. 2011;69(3):228-33.

Jerzykowska O, Kalmucki P, Woloszyn M, Smuszkiewicz P, Firek L, Siminiak T. Echocardiographic evaluation of percutaneous vavle repair in patients with mitral regurgitation using the Carillon system. Kardiol Pol. 2010;68(1):57-63.

Hoppe UC, Brandt MC, Degen H, Dodos F, Schneider T, Stoepel C, Kroener A, Haude M. Percutaneous mitral annuloplasty device leaves free access to cardiac veins for resynchronization therapy. Catheter Cardiovasc Interv. 2009;74(3):506-11.

Lainscak M, Bohm, M. Embracing secondary mitral regurgitation with Carillon: past, present, and future. ESC Heart Failure 2020; 7: 3268-3270.

Giallauria F, Di Lorenzo A, Parlato A, et. al. Individual patient data meta-analysis of the effects of the CARILLON® mitral contour system. ESC Heart Failure 2020; 7: 3383-3391.

Khan MS et al.; Functional outcomes with Carillon device over 1 year in patients with functional mitral regurgitation of Grades 2+ to 4+: results from the REDUCE-FMR trial; ESC Heart Failure (2021); Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/ehf2.13273.

Khan MS et al.; Effect of Carillon Mitral Contour System on patient‐reported outcomes in functional mitral regurgitation: an individual participant data meta‐analysis; Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/ehf2.13301.

Anker SD, Starling RC, Khan MS, Friede T, Filippatos G, Lindenfeld J, Stephan von Bardeleben R, Coats AJS, Butler J. Percutaneous Mitral Valve Annuloplasty in Patients With Secondary Mitral Regurgitation and Severe Left Ventricular Enlargement. JACC Heart Fail. 2021. doi: 10.1016/j.jchf.2021.03.002.

Klaus K Witte, David M Kaye, Janusz Lipiecki, Tomasz Siminiak, Steven L Goldberg, Ralph S von Bardeleben, Horst Sievert, Wayne C Levy, Randall C Starling. Treating symptoms and reversing remodelling: clinical and echocardiographic 1-year outcomes with percutaneous mitral annuloplasty for mild to moderate secondary mitral regurgitation.
Eur J Heart Fail. 2021. doi: 10.1002/ejhf.2310.

Piotr Nikodem Rudziński, Markus Mach, Christoph Gross, Martin Andreas. Complex transcatheter aortic valve replacement in aortic regurgitation and transcatheter mitral annuloplasty in severe dextrocardia. Eur J Cardiothorac Surg. 2021. doi: 10.1093/ejcts/ezab124.

Amar Krishnaswamy, Samir R Kapadia. Indirect Mitral Annuloplasty Using the Carillon Device. Front Cardiovasc Med. 2020. doi: 10.3389/fcvm.2020.576058.

Kalmucki P, Lipiecki J, Witte K, Goldberg S, Baszko A, Siminiak T. Percutaneous mitral annuloplasty with the Carillon device: Outcomes in proportionate and disproportionate functional mitral regurgitation. Am Heart J 2023;265:137–142

Lipiecki, J, Kaye D, Witte K, Haude M, Kapadia S, Sievert H, Goldberg S, Levy W, Siminiak T.

Witte. New Results from the CINCH-FMR Post-Market Registry: Treatment of Heart Failure Patients with Functional Mitral Regurgitation with the Carillon Mitral Contour System. THT 2025. Symposium Presentation

Priebe-Brämer. 200+ Patients, Real-World Impact: Carillon Therapy in Routine Care. THT 2025. Symposium Presentation

Why the Carillon Mitral Contour System Matters

“Our patients don’t care if they have regurgitant volume when they come to the hospital. Their focus is around symptoms, quality-of-life, hospitalizations and, as the ultimate goal, long-term survival.”

Stefan Anker, MD

Professor of Cardiology

Charité University<br>Berlin, Germany

“I am very excited to launch the EMPOWER Trial. This will be the first time where we are able to study early intervention with a device in heart failure. This is an extremely large patient population that is currently not being studied by other novel therapies.”

Samir Kapadia, MD

Chairman of the Department of Cardiovascular Medicine

Cleveland Clinic<br>Cleveland, OH

“The improved survival rate outcomes for patients receiving the Carillon device compared to medical management of these heart failure patients is simply impressive.”

Janusz Lipiecki, MD

Center for Interventional Cardiology of Pôle Santé République

Clermont-Ferrand<br>Auvergne, France

“I’m so pleased. I’m not dizzy anymore. I don’t have breathing problems anymore. I don’t have to take pauses when shopping. I can do everything by myself again. Hooray!”

Gandula

Carillon patient

Germany

Latest News

September 3, 2025

William T. Abraham, MD, Joins Cardiac Dimensions as Chief Medical Officer

March 20, 2025

Cardiac Dimensions Raises $53 Million Series E Financing

March 4, 2025

Cardiac Dimensions in recent TCT MD publication

February 12, 2025

New Long-term Results from the CINCH-FMR Post-Market Registry

Join our mailing list for invitations to studies along with company announcements.

CAUTION: USA: Investigational device. Limited by Federal (or United States) law to investigational use.

Canada: Investigational device. To be used by qualified investigators only.

Cardiac Dimensions, Carillon, Carillon Mitral Contour System are registered trademarks of Cardiac Dimensions Pty Ltd.

The Carillon Mitral Contour System is CE Marked (0344) and is commercially available in Europe and other countries.